The Estée Lauder Companies Inc. (NYSE:EL) announced today the appointment of Michael O’Hare as Executive Vice President, Global Human Resources. Mr. O’Hare will report jointly to William P. Lauder, Executive Chairman, and Fabrizio Freda, President and Chief Executive Officer. He assumes his new position on September 30, 2013.

Mr. O’Hare joins the"...

With the global community marking World Refugee Day on June 20th, Her Highness Sheikha Jawaher Bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah and Chairperson of the Supreme Council for Family Affairs and UNHCR Eminent Advocate for Refugee Children has made the Syrian refugee crisis her immediate focus by launching the ‘Big Heart for Syrian refugee children’ campaign.

According"...

Quintiles (NYSE: Q) has been named to IDG’s Computerworld “100 Best Places to Work in IT” list for the fifth time.

Computerworld has recognized the top 100 companies for information technology professionals since 1994 based on criteria such as diversity, career development, training and retention.

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the final results of the PUFs (Pipeline for Uncoilable or Failed Aneurysms) clinical study of its Pipeline™ embolization device"......

The Worldwide Innovative Networking (WIN) Consortium, a leader in personalized cancer medicine, today proudly announced that the Blue Cross and Blue Shield Association (BCBSA), an association of thirty-eight independent Blue Cross and Blue Shield companies, has become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, insurance and patient advocacy organizations"...

Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.1

• Published online in Circulation, results from RELY-ABLE®, the RE-LY® extension study, support long-term safety of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation
• Pradaxa® is the only novel oral anticoagulant with controlled long-term clinical trial data extending beyond 4 years of ongoing treatment
• The long-term results contribute to the growing body of data reinforcing Pradaxa® as an important advancement in the treatment of patients with atrial fibrillation compared to warfarin1

For media outside USA, UK and Canada only

• In the Phase IIb SOUND-C3 study, all but one patient achieved viral cure with faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin, without a need for interferon
• The study included challenging-to-cure patients with advanced liver disease, all of whom achieved viral cure

New data from Boehringer Ingelheim’s"...

The Air Ambulance aircraft of the Abu Dhabi Police’s Air Wing Department airlifted an Emirati woman who had sustained injuries in a traffic accident, from Ibri hospital in the Sultanate of Oman to Tawam hospital in Al Ain to receive necessary medical treatment.

This comes in line with the humanitarian missions provided by the Department to the public.

Ex US & UK Medical Media Only

Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the companies’ diabetes alliance will have a strong scientific and clinical presence at the 73rd American Diabetes Association (ADA) Scientific Sessions® in Chicago, 21–25 June, with 34 posters, abstracts and an oral presentation.

Empagliflozin*"...